



Mylan's Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs

PITTSBURGH, June 1 /PRNewswire-FirstCall/ --

WHAT: Mylan Inc. (Nasdaq: MYL) has accepted an invitation to testify before the U.S. House of Representatives Judiciary Subcommittee on Courts and Competition Policy at its upcoming hearing: "Pay to Delay: Are Patent Settlements That Delay Generic Drug Market Entry Anticompetitive?" Mylan was invited to testify by Committee on the Judiciary Chairman Rep. John Conyers Jr. (D-MI).

WHO: Mylan Chief Operating Officer Heather Bresch will testify on behalf of the company. As part of Mylan's testimony, Bresch will address impediments that unfairly delay consumer access to affordable generic pharmaceuticals, including authorized generics during the 180-day exclusivity period.

WHEN: Wednesday, June 3, 2009 at 10:00 a.m.

WHERE: 2141 Rayburn House Office Building, Washington, D.C.

WEBCAST: www.judiciary.house.gov/hearings/calendar.html

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc. 06/01/2009 /CONTACT: Michael Laffin, +1-724-514-1968 /Web Site: <http://www.mylan.com> (MYL)